Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue
Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47% TORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced preliminary…
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
